Recursion Pharmaceuticals. has filed a patent for methods and compositions to treat lysosomal storage diseases and their symptoms. The patent claims a method of administering a compound containing a PKC inhibitor, a GSK3ß inhibitor, or an inhibitor of both to effectively treat the diseases and symptoms. GlobalData’s report on Recursion Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Recursion Pharmaceuticals, Vehicle driver physiological monitoring was a key innovation area identified from patents. Recursion Pharmaceuticals's grant share as of September 2023 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of lysosomal storage diseases using inhibitors of pkc and gsk3ß
A recently filed patent (Publication Number: US20230310377A1) describes a method for treating lysosomal storage diseases and their symptoms. The method involves administering a compound that includes a PKC inhibitor, a GSK3ß inhibitor, or an inhibitor of both to a patient in need of treatment. The compound can be ruboxistaurin, sotrastaurin, enzastaurin, LY2090314, AZD1080, AZD2858, prodrugs, active metabolites, analogs, or derivatives of these compounds, or a pharmaceutically acceptable salt, solvate, or ester of these compounds. The method can also include administering ruboxistaurin hydrochloride, sulfate, mesylate, succinate, tartrate, acetate, or phosphate, or ruboxistaurin mesylate monohydrate. The method can be administered orally or parenterally.
The patent also covers the treatment of diseases and symptoms associated with mutations in the hexosaminidase subunit alpha (HEXA) gene or hexosaminidase subunit beta (HEXB) gene. These diseases include Tay-Sachs disease, Sandhoff disease, and infantile GM2 gangliosidoses. The method can be used to treat symptoms such as progressive loss of motor skills, retinal abnormalities, myoclonic seizures, increased startle response, severe constipation, loss of visceral organ function, cherry red spot, hypotonia, dyskinesia, and dystonia.
The patent also describes a method of identifying patients with ganglioside accumulation by measuring GM2 fluorescence in cells obtained from the patient. The method can further include administering a compound comprising a PKC inhibitor, a GSK3ß inhibitor, or an inhibitor of both to the patient.
The patent also covers compositions for use in treating lysosomal storage diseases and their symptoms. These compositions include a therapeutically effective amount of a compound comprising a PKC inhibitor, a GSK3ß inhibitor, or an inhibitor of both. The compositions can be formulated for oral or parenteral administration.
Overall, this patent describes a method and compositions for treating lysosomal storage diseases and their symptoms, particularly those associated with mutations in the HEXA and HEXB genes. The method involves administering compounds that inhibit PKC and/or GSK3ß to patients in need of treatment. The compositions can be administered orally or parenterally.
To know more about GlobalData’s detailed insights on Recursion Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
